Eli Lilly And Co vs Nerdwallet Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Nerdwallet Inc trades at $9.74 (market cap $625.17M). The key difference: Eli Lilly And Co is far larger — about 1663.5× Nerdwallet Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Nerdwallet Inc for 45 Days on average.
| LLY | NRDS | |
|---|---|---|
Market Cap | $1.04T | $625.17M |
Volume | 3,064,878 | 1,321,316 |
Sector | Health | Media |
52-Week High | $1.28K | $15.93 |
52-Week Low | $799.57 | $7.58 |
Typical Hold Time | 93 Days | 45 Days |
Enterprise Value | $1.09T | $539.47M |
Dividend Yield | 0.59% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
NerdWallet (NRDS) trades at $9.79, up 7.76% with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with revenue growing from $539M in 2022 to $837M in 2025, though Q2 2026 earnings missed expectations. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81, while profitability metrics show ROE of 18.16% and net margin of 7.56%.
The stock presents a compelling growth story with accelerating revenue and improving margins, supported by 66.7% analyst buy ratings. Key risks include competitive pressure in organic search and execution challenges in maintaining earnings momentum. The positive cash flow trend and institutional support suggest potential for continued upside if the company can sustain its growth trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →